SCHEMBL3250940

SCHEMBL3250940

Nc1ncc(C#Cc2ccc(Cl)cc2)c(N2CCN(CCO)CC2)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 3/20 0.43
ROCK1 Q13464 3/20 0.43
DHFR P00374 1/20 0.39
ALDH1A1 P00352 2/20 0.39
HPGD P15428 1/20 0.39
HSD17B10 Q99714 1/20 0.39
METAP1 P53582 1/20 0.39
TP53 P04637 2/20 0.38
LMNA P02545 1/20 0.38
SRC P12931 1/20 0.38
MCHR1 Q99705 4/20 0.38
CHUK O15111 1/20 0.38
HTR2A P28223 1/20 0.38
HRH4 Q9H3N8 1/20 0.38
PI4KB Q9UBF8 1/20 0.37
KDM4E B2RXH2 1/20 0.37
USP2 O75604 1/20 0.37
MAPT P10636 1/20 0.37
TSHR P16473 1/20 0.37
CASP1 P29466 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3248485 0.89 KDM4E (0.46) ROCK2ROCK1ALDH1A1HSD17B10METAP1
SCHEMBL7708469 0.81 ROCK2 (0.49) ROCK2ROCK1DHFRALDH1A1HPGD
SCHEMBL3253547 0.81 PIK3CA (0.43) DHFRALDH1A1HPGDHSD17B10TP53
SCHEMBL3254294 0.80 ADK (0.49) DHFRKDM4E
SCHEMBL3244776 0.80 ADK (0.51) DHFRALDH1A1HPGDHRH4PI4KB
SCHEMBL7714413 0.79 ROCK2 (0.44) ROCK2ROCK1DHFRALDH1A1HPGD
SCHEMBL7708442 0.78 LMNA (0.45) ROCK2ROCK1DHFRALDH1A1HPGD
SCHEMBL7712408 0.78 ROCK2 (0.43) ROCK2ROCK1DHFRALDH1A1HPGD
SCHEMBL7708451 0.77 ROCK2 (0.43) ROCK2ROCK1DHFRALDH1A1HPGD
SCHEMBL3248491 0.75 ROCK2 (0.45) ROCK2ROCK1DHFRALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1303495-B1 SUBSTITUTED 5-ALKYNYL PYRIMIDINES HAVING NEUROTROPHIC ACTIVITY KRENITSKY PHARMACEUTICALS INC (US) 2010-05-26 EP claimed
US-7205297-B2 Substituted 5-alkynyl pyrimidines having neurotrophic activity KRENITSKY PHARMACEUTICALS, INC. (US) 2007-04-17 US claimed
US-20040087789-A1 Substituted 5-alkynyl pyrimidines having neurotrophic activity MIDCAP FUNDING III, LLC 2004-05-06 US claimed
EP-1303495-A1 SUBSTITUTED 5-ALKYNYL PYRIMIDINES HAVING NEUROTROPHIC ACTIVITY Krenitsky Pharmaceuticals, Inc. (US) 2003-04-23 EP claimed
WO-2002008205-A1 SUBSTITUTED 5-ALKYNYL PYRIMIDINES HAVING NEUROTROPHIC ACTIVITY KRENITSKY PHARMACEUTICALS, INC. (US) 2002-01-31 WO claimed
EP-1303495-B1 SUBSTITUTED 5-ALKYNYL PYRIMIDINES HAVING NEUROTROPHIC ACTIVITY KRENITSKY PHARMACEUTICALS INC (US) 2010-05-26 EP disclosed
US-7205297-B2 Substituted 5-alkynyl pyrimidines having neurotrophic activity KRENITSKY PHARMACEUTICALS, INC. (US) 2007-04-17 US disclosed
US-20040087789-A1 Substituted 5-alkynyl pyrimidines having neurotrophic activity MIDCAP FUNDING III, LLC 2004-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040087789-A1 Substituted 5-alkynyl pyrimidines having neurotrophic activity BDNF, NTRK2, GAP43 ROCK2 3363/4885ROCK1 3019/4885DHFR 1307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.